Loading
メディシノバ・インク Stock: price and insider trades · Japan
JP·Mcap JP¥11.7B
メディシノバ・インク: what insiders have been doing
Only a handful of insider records exist for メディシノバ・インク, the last one from 2 October 2026, too few to describe a trend. Source: insider filings from EDINET (Japan FSA). Past trades are no guide to future returns.
Insider Decl.
3
Thresholds
n/a
Buy Volume
n/a
n/a
Sell Volume
n/a
n/a
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Fundamental score
Ranked 21,855 of 24,148 companies
21.6
score / 100
Value34
Quality9
FCF yld-0.1%
Earn yld-0.1%
EV/EBITDA·
ROE-26%
Gross mgn7.6%
Net mgn·
Debt/EBITDA·
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Financial data
as of FY 2025FY ended December 2025 · cache
JP¥237
Analyst consensus
1.25/5
Income statement
RevenueJP¥409.7k
Gross profitJP¥31.1k8% margin
EBITDA-JP¥13.3M-3238% margin
Net income-JP¥12M-2928.8% margin
Valuation
PER (forward)-2.9x
P/Book2.0x
Beta0.61
Balance sheet & cash
Market capJP¥11.7B
Total debtJP¥194.3k
Free Cash Flow-JP¥9.8M
Debt / Equity0%
Profitability & ownership
ROE-25.6%
ROA-16.4%
% insiders2.9%
% institutions20.4%
Last declaration on 2 October 2026
Declarations3 total
100.0% of flowShareXTKSEDINET:S100Z626
49.0% of flowShareXTKSEDINET:S100SYE6
51.0% of flowShareXTKSEDINET:S100SY4G
3 of 3 declarations
About メディシノバ・インク
Medicinova, Inc. is a biopharmaceutical company focused on developing treatments for neurological diseases and psychiatric disorders. It is listed on the Tokyo Stock Exchange under the symbol XTKS.